Osteonecrosis of the Jaw

B Lončar Brzak, L Horvat Aleksijević, E Vindiš, I Kordić… - Dentistry journal, 2023 - mdpi.com
Osteonecrosis of the jaw is a condition in which bone cells die due to various causes. It is
classified as drug-induced jaw osteonecrosis, osteoradionecrosis, traumatic, non-traumatic …

Unraveling the Role of Endothelial Dysfunction in Osteonecrosis of the Femoral Head: A Pathway to New Therapies

W Shao, P Wang, X Lv, B Wang, S Gong, Y Feng - Biomedicines, 2024 - mdpi.com
Osteonecrosis of the femoral head (ONFH) is a disabling disease characterized by the
disruption of the blood supply to the femoral head, leading to the apoptosis and necrosis of …

Osteonecrosis of the jaw associated with pembrolizumab

I Pennings, A Moskowitz, G Shah, C Estilo… - Oral Surgery, Oral …, 2023 - Elsevier
We report a case of osteonecrosis of the jaw (ONJ) with pembrolizumab, a rare yet possibly
emerging complication. In this case, a temporal relationship between the development of …

[HTML][HTML] COVID-19 as a critical risk factor for osteonecrosis of the jaw: diagnostic challenge and surgical treatment

A Romano, R Gasparro, MD Campana… - Current Problems in …, 2024 - Elsevier
Aspergillosis encompasses a spectrum of clinical diseases, ranging from asymptomatic
infection and colonization to life-threatening invasive conditions. Typically, this infection first …

Predictive Value of Neutrophil–Lymphocyte Ratio as a Marker in Antiresorptive Agent-Related Osteonecrosis of the Jaw: A Retrospective Analysis

K Kurohara, K Shimizu, T Murata, G Koizumi… - Diagnostics, 2022 - mdpi.com
Antiresorptive agent-related osteonecrosis of the jaw (ARONJ), a multifactorial disease, can
drastically affect a patient's quality of life. Moreover, disease progression to severe acute …

Incidence and Risk of Anti-Resorptive Agent-Related Osteonecrosis of the Jaw after Tooth Extraction: A Retrospective Study

R Shimizu, S Sukegawa, Y Sukegawa, K Hasegawa… - Healthcare, 2022 - mdpi.com
Bone-modifying agents (BMA) such as bisphosphonates and denosumab are frequently
used for the treatment of bone metastases, osteoporosis, and multiple myeloma. BMA may …

[PDF][PDF] Incidence and risk of anti-resorptive agent-related osteonecrosis of the jaw after tooth extraction: a retrospective study. Healthcare (Basel) 2022; 10

R Shimizu, S Sukegawa, Y Sukegawa, K Hasegawa… - 2022 - academia.edu
Bone-modifying agents (BMA) such as bisphosphonates and denosumab are frequently
used for the treatment of bone metastases, osteoporosis, and multiple myeloma. BMA may …

ASPECTOS CLÍNICOS E TERAPÊUTICOS DA OSTEONECROSE DA MANDÍBULA: IMPLICAÇÕES PARA A PRÁTICA ODONTOLÓGICA

AC Paiva, JCGA Moretti, IM Beneti… - REVISTA …, 2024 - ojs.focopublicacoes.com.br
A osteonecrose da mandíbula (ONM) é uma condição patológica grave que pode levar a
complicações severas como dor, infecção e perda de dentes, afetando significativamente a …

Osteonecrosis of the Jaw.

E Vindiš, I Kordić, M Granić - Dentistry Journal, 2023 - europepmc.org
Osteonecrosis of the jaw is a condition in which bone cells die due to various causes. It is
classified as drug-induced jaw osteonecrosis, osteoradionecrosis, traumatic, non-traumatic …